DK3228313T3 - Doseringsformer og terapeutiske anvendelser af L-4-chlorkynurenin - Google Patents
Doseringsformer og terapeutiske anvendelser af L-4-chlorkynurenin Download PDFInfo
- Publication number
- DK3228313T3 DK3228313T3 DK17170079T DK17170079T DK3228313T3 DK 3228313 T3 DK3228313 T3 DK 3228313T3 DK 17170079 T DK17170079 T DK 17170079T DK 17170079 T DK17170079 T DK 17170079T DK 3228313 T3 DK3228313 T3 DK 3228313T3
- Authority
- DK
- Denmark
- Prior art keywords
- chloroquinurenine
- dosage forms
- therapeutic applications
- therapeutic
- applications
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Lubricants (AREA)
- Cosmetics (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361849191P | 2013-01-22 | 2013-01-22 | |
| EP14743570.5A EP2948140B1 (en) | 2013-01-22 | 2014-01-22 | Dosage forms and therapeutic uses l-4-chlorokynurenine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3228313T3 true DK3228313T3 (da) | 2019-11-25 |
Family
ID=51228003
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17170079T DK3228313T3 (da) | 2013-01-22 | 2014-01-22 | Doseringsformer og terapeutiske anvendelser af L-4-chlorkynurenin |
| DK19196366.9T DK3598971T3 (da) | 2013-01-22 | 2014-01-22 | Doseringsformer og terapeutiske anvendelser af L-4-chlorkynurenin |
| DK14743570.5T DK2948140T3 (en) | 2013-01-22 | 2014-01-22 | DOSAGE FORMS AND THERAPEUTIC APPLICATIONS OF L-4-CHLORCYNURENINE |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK19196366.9T DK3598971T3 (da) | 2013-01-22 | 2014-01-22 | Doseringsformer og terapeutiske anvendelser af L-4-chlorkynurenin |
| DK14743570.5T DK2948140T3 (en) | 2013-01-22 | 2014-01-22 | DOSAGE FORMS AND THERAPEUTIC APPLICATIONS OF L-4-CHLORCYNURENINE |
Country Status (22)
| Country | Link |
|---|---|
| US (8) | US9993450B2 (https=) |
| EP (4) | EP2948140B1 (https=) |
| JP (5) | JP6436913B2 (https=) |
| KR (5) | KR20230003410A (https=) |
| CN (4) | CN112933073A (https=) |
| AU (5) | AU2014209466B2 (https=) |
| BR (1) | BR112015017535A2 (https=) |
| CA (3) | CA3128321C (https=) |
| CY (1) | CY1122403T1 (https=) |
| DK (3) | DK3228313T3 (https=) |
| ES (3) | ES2980120T3 (https=) |
| HK (1) | HK1217170A1 (https=) |
| HR (2) | HRP20240812T1 (https=) |
| HU (1) | HUE067381T2 (https=) |
| IL (3) | IL291831B1 (https=) |
| MX (2) | MX375318B (https=) |
| PL (2) | PL3598971T3 (https=) |
| PT (3) | PT3598971T (https=) |
| RS (1) | RS59687B1 (https=) |
| SI (2) | SI3228313T1 (https=) |
| WO (1) | WO2014116739A1 (https=) |
| ZA (2) | ZA201505569B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3598971T (pt) | 2013-01-22 | 2024-06-20 | Vistagen Therapeutics Inc | ¿formas de dosagem e utilizações terapêuticas de l-4 cloroquinurenina |
| JP2018521007A (ja) * | 2015-05-22 | 2018-08-02 | ヴィスタゲン セラピューティクス、インコーポレイテッド | Ｌ−４−クロロキヌレニンの治療的使用 |
| WO2017044516A1 (en) * | 2015-09-08 | 2017-03-16 | Cephalon, Inc. | Prodrugs of chlorokynurenines |
| CN118026866A (zh) | 2018-02-09 | 2024-05-14 | 维斯塔津治疗公司 | 4-氯代犬尿氨酸及中间体的合成 |
| CN109223785A (zh) * | 2018-10-29 | 2019-01-18 | 中国药科大学 | 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用 |
| WO2022082100A1 (en) * | 2020-10-16 | 2022-04-21 | Vistagen Therapeutics, Inc. | Cocrystals of l-4-chlorokynurenine, compositions and therapeutic uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5086072A (en) * | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| US5360814A (en) | 1991-02-28 | 1994-11-01 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
| US5484814A (en) | 1991-02-28 | 1996-01-16 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| TW518218B (en) | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| WO2003015713A2 (en) | 2001-08-20 | 2003-02-27 | Maiken Nedergaard | Treatment of glial tumors with glutamate antagonists |
| JP2006502158A (ja) | 2002-09-06 | 2006-01-19 | デュレクト コーポレーション | グルタメート媒介神経伝達のモジュレーターの内耳への送達 |
| US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| AU2007235876A1 (en) | 2006-04-12 | 2007-10-18 | Probiodrug Ag | Enzyme inhibitors |
| EP1903028A1 (en) * | 2006-09-22 | 2008-03-26 | Werner Tschollar | Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects |
| US8058243B2 (en) | 2006-10-13 | 2011-11-15 | Hsc Research And Development Limited Partnership | Method for treating a brain cancer with ifenprodil |
| EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| WO2009135091A1 (en) * | 2008-04-30 | 2009-11-05 | Medivation Technologies, Inc. | Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions |
| US20110190347A1 (en) | 2008-08-21 | 2011-08-04 | Richter Gedeon Nyrt. | Methods for treating neuropathic pain |
| ES2612948T3 (es) | 2009-04-23 | 2017-05-19 | Universität Zürich | Bloqueantes del receptor de NMDA para el tratamiento de anemia falciforme |
| BRPI1014247A2 (pt) * | 2009-06-17 | 2016-04-12 | Targacept Inc | reversão da discinesia induzida pela l-dopa por ligantes de receptores nocotínicos neuronais. |
| DK2466312T3 (da) | 2009-08-12 | 2020-01-13 | Human Metabolome Tech Inc | Phosphoethanolamine som biomarkør for depression |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| EP2338873A1 (en) * | 2009-12-22 | 2011-06-29 | Gmeiner, Peter | New aminotetraline derivatives |
| EP2992877A1 (en) * | 2010-06-15 | 2016-03-09 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| PT3598971T (pt) | 2013-01-22 | 2024-06-20 | Vistagen Therapeutics Inc | ¿formas de dosagem e utilizações terapêuticas de l-4 cloroquinurenina |
| WO2014152835A1 (en) | 2013-03-14 | 2014-09-25 | Vistagen Therapeutics, Inc. | Synthesis of chiral kynurenine compounds and intermediates |
| US9745342B2 (en) | 2013-10-28 | 2017-08-29 | Naurex, Inc. | NMDA receptor modulators and prodrugs, salts, and uses thereof |
| JP2018521007A (ja) | 2015-05-22 | 2018-08-02 | ヴィスタゲン セラピューティクス、インコーポレイテッド | Ｌ−４−クロロキヌレニンの治療的使用 |
-
2014
- 2014-01-22 PT PT191963669T patent/PT3598971T/pt unknown
- 2014-01-22 KR KR1020227044517A patent/KR20230003410A/ko not_active Ceased
- 2014-01-22 SI SI201431410T patent/SI3228313T1/sl unknown
- 2014-01-22 HR HRP20240812TT patent/HRP20240812T1/hr unknown
- 2014-01-22 CA CA3128321A patent/CA3128321C/en active Active
- 2014-01-22 KR KR1020157022405A patent/KR102257284B1/ko active Active
- 2014-01-22 DK DK17170079T patent/DK3228313T3/da active
- 2014-01-22 CA CA2898619A patent/CA2898619C/en active Active
- 2014-01-22 CN CN202110387961.2A patent/CN112933073A/zh active Pending
- 2014-01-22 EP EP14743570.5A patent/EP2948140B1/en active Active
- 2014-01-22 DK DK19196366.9T patent/DK3598971T3/da active
- 2014-01-22 JP JP2015553921A patent/JP6436913B2/ja active Active
- 2014-01-22 BR BR112015017535-0A patent/BR112015017535A2/pt not_active IP Right Cessation
- 2014-01-22 HU HUE19196366A patent/HUE067381T2/hu unknown
- 2014-01-22 IL IL291831A patent/IL291831B1/en unknown
- 2014-01-22 PT PT171700792T patent/PT3228313T/pt unknown
- 2014-01-22 US US14/762,015 patent/US9993450B2/en active Active
- 2014-01-22 AU AU2014209466A patent/AU2014209466B2/en active Active
- 2014-01-22 WO PCT/US2014/012598 patent/WO2014116739A1/en not_active Ceased
- 2014-01-22 DK DK14743570.5T patent/DK2948140T3/en active
- 2014-01-22 SI SI201432078T patent/SI3598971T1/sl unknown
- 2014-01-22 CA CA3216579A patent/CA3216579A1/en active Pending
- 2014-01-22 CN CN202110387953.8A patent/CN113209068A/zh active Pending
- 2014-01-22 CN CN201480010060.XA patent/CN105073108A/zh active Pending
- 2014-01-22 KR KR1020237021428A patent/KR20230098711A/ko not_active Ceased
- 2014-01-22 HK HK16105132.0A patent/HK1217170A1/zh unknown
- 2014-01-22 ES ES19196366T patent/ES2980120T3/es active Active
- 2014-01-22 PL PL19196366.9T patent/PL3598971T3/pl unknown
- 2014-01-22 PL PL17170079T patent/PL3228313T3/pl unknown
- 2014-01-22 KR KR1020217015432A patent/KR102335919B1/ko active Active
- 2014-01-22 CN CN202110384159.8A patent/CN113116877A/zh active Pending
- 2014-01-22 EP EP19196366.9A patent/EP3598971B1/en active Active
- 2014-01-22 KR KR1020217039478A patent/KR20210149905A/ko not_active Ceased
- 2014-01-22 ES ES17170079T patent/ES2751138T3/es active Active
- 2014-01-22 EP EP24164414.5A patent/EP4385563A3/en not_active Withdrawn
- 2014-01-22 MX MX2015009277A patent/MX375318B/es active IP Right Grant
- 2014-01-22 EP EP17170079.2A patent/EP3228313B1/en active Active
- 2014-01-22 RS RS20191519A patent/RS59687B1/sr unknown
- 2014-01-22 ES ES14743570.5T patent/ES2635353T3/es active Active
- 2014-01-22 PT PT147435705T patent/PT2948140T/pt unknown
-
2015
- 2015-07-17 MX MX2020009966A patent/MX2020009966A/es unknown
- 2015-07-22 IL IL240090A patent/IL240090B/en active IP Right Grant
- 2015-08-03 ZA ZA2015/05569A patent/ZA201505569B/en unknown
-
2016
- 2016-02-08 US US15/018,219 patent/US9993453B2/en active Active
- 2016-11-02 ZA ZA2016/07581A patent/ZA201607581B/en unknown
-
2018
- 2018-05-14 US US15/978,855 patent/US10632091B2/en active Active
- 2018-06-08 US US16/003,816 patent/US10980758B2/en active Active
- 2018-06-08 US US16/003,793 patent/US10617663B2/en active Active
- 2018-06-08 US US16/003,804 patent/US20180369180A1/en not_active Abandoned
- 2018-09-13 JP JP2018171786A patent/JP6804497B2/ja active Active
- 2018-10-26 AU AU2018253600A patent/AU2018253600B2/en active Active
-
2019
- 2019-11-27 CY CY20191101244T patent/CY1122403T1/el unknown
- 2019-12-04 HR HRP20192189TT patent/HRP20192189T1/hr unknown
-
2020
- 2020-07-01 AU AU2020204420A patent/AU2020204420A1/en not_active Abandoned
- 2020-07-03 JP JP2020115273A patent/JP7021298B2/ja active Active
- 2020-07-16 IL IL276126A patent/IL276126B/en unknown
-
2022
- 2022-02-03 JP JP2022015622A patent/JP2022070894A/ja active Pending
- 2022-06-21 US US17/845,105 patent/US12036198B2/en active Active
- 2022-08-22 AU AU2022221382A patent/AU2022221382B2/en active Active
-
2024
- 2024-02-27 JP JP2024027330A patent/JP2024069257A/ja active Pending
- 2024-03-21 US US18/611,908 patent/US20250161251A1/en active Pending
- 2024-12-18 AU AU2024278564A patent/AU2024278564A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2981255T3 (da) | Terapeutiske anvendelser af empagliflozin | |
| PL4234581T3 (pl) | Przeciwciała terapeutyczne i ich zastosowania | |
| DK2968208T3 (da) | Behandling af kataplexi | |
| IL244259B (en) | Delivery of medical devices | |
| DK3021838T3 (da) | Behandling af fedme | |
| HRP20190101T1 (hr) | Terapeutske uporabe empagliflozina | |
| DK3080100T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| DK3043784T3 (da) | Arylethere og anvendelser deraf | |
| DK3083616T3 (da) | Bicykliske heterocykliske forbindelser og disses anvendelser i terapi | |
| DK2968443T3 (da) | Hepcidinanaloger og anvendelser deraf | |
| DK2958588T3 (da) | Kombination af vaccination og hæmning af PD-1-reaktionsvejen | |
| DK2961388T3 (da) | Kombinationer af lægemidler | |
| HRP20180684T1 (hr) | Kombinacija lijekova | |
| DK3003039T3 (da) | Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser | |
| DK3027618T3 (da) | Polymorf af syk-hæmmere | |
| DK2981541T3 (da) | Syntese og anvendelse af isotopmærkede glycaner | |
| HRP20170840T1 (hr) | Supstituirani ksantini i metode njihove uporabe | |
| DK3076972T3 (da) | Cancerbehandling med kombination af plinabulin og taxan | |
| DK3083789T3 (da) | Overfladebehandling af partikler og anvendelse heraf | |
| DK3626270T3 (da) | Behandling af kardiovaskulære sygdomme | |
| DK2964255T3 (da) | Behandling og forebyggelse af fjerntliggende iskæmi-reperfusionsskade (IRI) | |
| DK4335517T3 (da) | Indgivelse og dosering af diaminofenothiaziner | |
| DK2962100T3 (da) | Tuberkulosebiomarkører og anvendelser deraf | |
| DK2994157T3 (da) | Tafa4-forbindelser og anvendelser deraf til behandling af smerte | |
| HUE036672T2 (hu) | Pirazol-amid vegyület és gyógyászati alkalmazásai |